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Abstract
Purpose: This study, conducted in five safety-net practices, including two
nurse-managed health centers (NMHCs) and three federally qualified health
centers (FQHCs), examined the impact of implementing a commercial elec-
tronic health records (EHRs) system on medication safety.
Data source: A mixed methods approach with two sources of data were
used: (a) a query of prescription records captured by the EHR retrieving co-
prescribed medications with identified drug–drug interaction (DDI) risks, and
(b) semistructured interviews with clinicians and leadership about the usabil-
ity and benefits of EHR-embedded clinical decision support in the form of DDI
alerts.
Conclusions: We found an exceptionally low rate of DDI pairs in all five prac-
tices. Only 130 “true” DDI pairs were confirmed representing 149,087 visits
and 62 providers. Among the 130, the largest categories were related to anti-
hypertensive medications, which are in fact often prescribed together. There
were no significant differences between physicians and nurse practitioners on
the rate of DDI pairs nor between NMHCs and FQHCs.
Implications for practice: Implementation of an EHR in these five safety-
net settings had a positive impact on medication safety. The issue of missing
end dates is noteworthy in terms of DDIs and unnecessary alerts that could
lead to alert fatigue.
Introduction
Medication errors in both inpatient and primary care
settings account for a significant number of adverse
events and patient deaths. It is estimated that there are
1.5 million preventable adverse drug events annually in
the United States (Institute of Medicine [IOM], 2000,
2006). Electronic health record (EHR) systems hold enor-
mous promise in reducing errors in prescribing in all set-
tings (Kaushal, Shojania, & Bates, 2003; Kuo, Phillips,
Graham, & Hickner, 2008; Nemeth & Wessell, 2010).
However, much of the research to date has focused
more on inpatient settings than on primary care settings
(Kaushal et al., 2003; Wang et al., 2009).
At the same time, prescribing errors among
community-based providers who do not have EHRs
have been documented to be as high as one in every
four prescriptions written (Abramson et al., 2012). Other
researchers have determined that many of the prescrib-
ing errors in these community-based practices could
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Table 1 Description of participating centers
Center name and location Center type Annual visit volume Population served Type of care
CHC1, Mid-West FQHC >42,000 Urban Hispanic and recent
Mexican and Puerto Rican
Primary care OB/GYN Internal
Medicine Pediatric
CHC2, Mid-West FQHC >10,000 Urban, HIV+ gay, lesbian,
bisexual, and transgender
Primary care large mental health
and substance abuse
programs
CHC3, Mid-West FQHC >14,000 Urban homeless, migrant, and
recent refugee
Primary care mental health
OB/GYN
NMHC1, Mid-West NMHC 9000 College students, staff, and
families
Primary care
NMHC2, West Coast NMHC and FQHC 13,000 Urban, homeless ﬁnancially
disadvantaged
Primary care, mental health
complimentary care HIV
testing and risk reduction
have been avoided with the adoption of an EHR system
that has e-prescribing and decision-support capabilities
(Abramson et al., 2012; Kuo et al., 2008). Because of
widely anticipated patient safety benefits of EHRs, and
known deficiencies with handwritten prescriptions such
as poor legibility, the requirement to document and
transmit prescriptions has been included as an important
component of ambulatory incentive programs such as
“Meaningful Use” and Patient Centered Medical Home
(PCMH; Blumenthal & Tavenner, 2010; Sia, Tonniges,
Osterhus, & Taba, 2004).
And yet, issues related to functionality and usability
continue to limit the benefits of EHRs on prescribing er-
rors (Nanji et al., 2011). As an example, findings indicate
that alert fatigue is a major problem with the use of EHRs
in ambulatory settings (Isaac et al., 2009; van der Sijs,
Aarts, Vulto, & Berg, 2006). Overriding drug–drug inter-
action (DDI) alerts was found to be very common even
with high severity alerts in a study based on over 3 mil-
lion prescriptions, suggesting that current computerized
alert functions may actually be inadequate to protect pa-
tients (Isaac et al., 2009).
The present study was conducted in five safety-net
settings, including two nurse-managed health centers
(NMHCs) and three federally qualified health centers
(FQHCs), all using the same commercial EHR system.
Safety-net settings are critical to addressing the health-
care needs of very vulnerable populations who may seek
care more episodically, relocate more often, and have
more challenges with the overall healthcare system be-
cause of their less consistent access to insurance—all of
which can present an escalated level of patient safety is-
sues related to medications. With the literature suggest-
ing high rates of prescribing error among community-
based providers who do not have EHRs (Abramson et al.,
2012), EHRs hold promise for these settings in terms of
managing safer prescribing and clearer documentation of
medications. There are only limited data from safety-net
providers on the impact of EHRs on prescribing patterns
(e.g., Shields et al., 2007); information describing such
patterns in NMHCs is nonexistent.
This study was undertaken to better understand the
prevalence of medication errors in community primary
care settings where a commercial EHR system had been
newly implemented. The study utilized access to a cen-
tralized research database populated by the EHRs used
in five primary care practices to measure the extent
to which drug pairs with potential harmful interactions
were prescribed simultaneously to the same individual
(hereafter, DDI pairs). In addition, semistructured in-
terviews with provider informants were conducted and
qualitative analyses were performed to develop themes
relating to role of EHR use on medication safety. Study
protocols were approved by institutional review boards
with Federal Wide Assurance at the Michigan Public
Health Institute, University of Michigan, and relevant
sites.
Methods
This study was part of a larger project on EHR im-
plementation, clinician utilization, and quality of care
funded by the Agency for Healthcare Research and Qual-
ity (AHRQ) that began in September 2007 and concluded
in September 2011. The characteristics of the five safety-
net settings studied are reported in Table 1. These partic-
ipating heath centers provide primary care services to a
variety of populations and are located in multiple states
(Illinois, Michigan, and California). All of them utilize a
common EHR via a Health Center Controlled Network
supported by Alliance of Chicago Community Health Ser-
vices, a funding partner of the Chicago Health Informa-
tion Technology Regional Extension Center. Study pro-
tocols were approved by institutional review boards with
Federal Wide Assurance at the Michigan Public Health
Institute, the University of Michigan, and relevant sites.
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Table 2 Drug–drug interaction classiﬁcationsa
Severity—the medical risk of the interaction
3—Major Interaction may be life threatening or cause permanent damage
2—Moderate Patient’s condition may deteriorate because of interaction, requiring additional care
1—Minor Designates an interaction that is bothersome, but otherwise not medically detrimental
0—None Interaction has no documented clinical effect, according to published literature
Certainty—quality and quantity of medical literature supporting the existence of a detrimental interaction
5—Established Interaction proven in well-controlled human studies
4—Probable Pharmacokinetic changes documented and known to be of sufﬁcient magnitude to alter the therapeutic response
3—Suspected Pharmacokinetic changes possibly documented in well-controlled studies, but relationship between plasma
concentrations and pharmacologic effect not conﬁrmed
2—Possible Pharmacokinetic data, demonstrated pharmacologic response, or case reports suggest a possible interaction.
However, quality or quantity of supporting clinical data do not substantiate predictability of interaction
1—Doubtful, unknown Clinical documentation is of poor quality, or well-controlled studies refute case reports of interaction
aFrom Drug Therapy Monitoring System (DTMS) Reference Manual, Chapter 2—Clinical Deﬁnitions and Terminology (Published 05/97, Revised 03/01).
The model for EHR implementation in our project is
described elsewhere (removed for review, 2011) and was
developed based on the following three premises: (a) an
engaging and sustaining relationship with the technology
team is the only way to shield healthcare practices from
adoption difficulties and uncertainties (i.e., partnership-
based); (b) adopting practices should think and act col-
lectively as a community in order to lower purchase and
maintenance costs and jointly develop best practices for
implementation and use (i.e., community-oriented); and
(c) it is central to have strong commitments by all par-
ties to managing EHR implementation as a long-term,
continuous quality improvement process, as opposed to
a one-time software installation effort. The EHR utilized
the Medi-Span drug therapy monitoring system popu-
larly used in commercial EHR products, which provides
multiple levels of DDI and allergy alert sensitivity based
on an internal twofold classification of potential inter-
actions: (a) the severity of interaction outcomes (Major,
Moderate, Minor, None), and (b) level of evidence for
interactions (Established, Probable, Suspected, Possible,
Doubtful/Unknown). Table 2 defines the categories.
This article draws on two sources of data: (a) a query
of prescription records captured by the EHR retriev-
ing co-prescribed medications with identified interaction
risks, and (b) semistructured interviews with clinicians
and leadership about the usability and benefits of EHR-
embedded clinical decision support in the form of DDI
alerts. The study operationalized the concept of a “DDI
pair” as an instance in which a patient record showed two
drugs with documented potential interaction effects and
overlapping or partially overlapping in time. Therefore,
the DDI pairs used in this research study were obtained
through the following two sources. First, the project uti-
lized the DDI Quality Tool developed by the Centers for
Medicaid and Medicare Services (CMS) that measures
“the percent of Medicare Part D beneficiaries who re-
ceived a prescription for a target medication during the
measurement period and who were dispensed a prescrip-
tion for a contraindicated medication with or subsequent
to the initial prescription” (CMS, 2007). The second set
of DDI pairs was compiled by documenting all instances
during a preload of medical records into the system at one
of the participating health centers, which produced a list
of interacting drugs that approximates the DDI database
used in Medi-Span. For this method, a DDI pair was
identified when the EHR-generated alert met the thresh-
old of a “probable” or “established” “major” interaction
(Table 2).
The CMS tool contained 26 common DDI pairs. An-
other eight DDI pairs were further identified from the
preload data at the NMHC, resulting in a total of 34 DDI
pairs used in this study. The DDI query was run on the
EHR data of the participating health centers and covered
all of the 34 possible DDI pairs identified as being pre-
scribed to the same patient with overlapping start and end
dates during a 24-month period: September 2008–August
2010. Once the DDI pairs were identified, they were also
compared to an additional drug to drug checker (Facts
and Comparisons) to validate the levels of severity results
the EHR alert gave and to review additional advice for
each DDI pair. We also reviewed all DDIs with a pharma-
cist with expertise in primary care to better understand
the nature of these interacting drug pairs and how they
are handled by providers in typical patient care practices.
Quantitative data were supplemented with 14 provider
interviews, which took place 9–34 months after the EHR
“went live.” Respondents included four physicians, nine
nurse practitioners (NPs), and one psychologist. Inter-
views were semistructured, with questions centering on
the following topics: vision and goals for implement-
ing an EHR, the implementation process, leadership and
change management, perceived benefits, key challenges
to implementing and using, and the usability of clinical
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Table 3 DDIa pairs total with overlapping end dates (N = 641) and DDI pairs identiﬁed as “Deﬁnitely” or “Likely” (N = 130)
All DDI pairs DDI pairs of “Deﬁnitely” and
identiﬁed (N = 641) “Likely” (N = 130)
Source of
DDI pairs DDIb n % n %
ACE inhibitors + potassium sparing diuretics CMS 125 19.5 17 13
ARBs (angiotensin II receptor blockers) +
potassium sparing diuretics
CMS 39 6.1 10 7.7
Beta blockers + alpha agonists (clonidine) CMS 110 17.2 22 17
Beta blockers + calcium channel blockers CMS 122 19.0 23 17.7
Warfarin + NSAID CMS and preload 74 11.5 19 14.6
Warfarin + thyroid hormones CMS 18 2.8 3 2.3
Warfarin + macrolide antibiotics CMS and preload 16 2.5 6 4.6
Warfarin + sulfonamide CMS 12 1.9 1 0.8
Warfarin + amiodarone CMS 9 1.4 2 1.5
Warfarin + quinolone CMS 8 1.2 3 2.3
Warfarin + metronidazole CMS 5 0.8 3 2.3
Warfarin + dicloxacillin CMS 2 0.3 – –
Warfarin + tetracycline CMS 2 0.3 – –
Statin + antifungal tabs Preload 46 7.2 – –
Statin + calcium channel blockers Preload 20 3.1 5 3.8
Statin + macrolide Preload 14 2.2 11 8.5
Statin + prevpac misc Preload 4 0.6 1 0.8
Hydrochlorothiazide + lithium carbonate Preload 7 1.1 1 0.8
Potassium chloride + spironolactone tabs Preload 4 0.6 2 1.5
Methotrexate + trimethoprim CMS 2 0.3 1 0.8
Digoxin + macrolides CMS 2 0.3 – –
aDDI, drug to drug interaction.
bCMS tool versus preload data.
decision support features including medication safety
alerts. Nine interviews were conducted in person and five
were completed on the phone.
Interviews were recorded, transcribed, coded, and
analyzed using NVivo (QSR International, Doncaster,
Australia). We performed inductive open coding of the
interview transcripts and used the constant comparison
approach to identify salient, recurring themes (Charmaz,
2006; Glaser & Strauss, 1967).
Results
Quantitative analysis results
The DDI query revealed a total of 641 potential DDI
pairs across all five health centers over the 24-month
period, representing 149,087 visits and 62 providers. Of
these visits, 130,459 were from the three FQHCs and
18,628 were from the two NMHCs. A large majority of
the providers were from the FQHCs (n = 57).
Upon inspection of initial results, the research team
questioned the extent to which individual instances are
true DDI pairs, or whether apparent DDI pairs may be an
artifact of system use. Specifically, examination of these
data revealed that 564 of the 641 DDI pairs (88%) had
a missing end date on one or both drugs—labeled by the
DDI query as “potentially overlapping”—leaving only 77
DDI pairs that were “definitely” overlapping in time (12%
of the total 641 DDI pairs) during the study timeframe.
Of the 564 DDIs that had one or more missing end dates,
511 (80% of total DDIs) were categorized as “unlikely”
because of the fact that their start dates were greater than
1 month apart and/or they were prescribed prior to the
beginning of our study period (September 1, 2008). The
53 remaining DDI pairs (8% of total DDIs) with missing
end date(s) were considered “likely,” as both drugs were
prescribed on or after September 1, 2008 and had start
dates within 1 month of each other, indicating a higher
likelihood that the prescriptions overlapped during the
study period. We ultimately decided to restrict our query
to include the 77 “definitely” DDI pairs with specifically
documented start and end dates and the 53 “likely” DDI
pairs for a total of 130 DDIs for 149,081 patient visits.
The distribution of all 641 DDI pairs and the distribution
of the 130 “definitely” and “likely” pairs are presented in
Table 3. Of the 34 possible DDI pairs queried, we found
21 DDI pairs in the 641 sample and 14 DDI pairs in the
130 sample (Table 3).
Of the 77 “definite” DDI pairs, six were from one
NMHC and 71 were from the three FQHCs. For the
“likely” category, eight of the 53 DDI pairs were from
one NMHC and the other 45 were from the three FQHCs.
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Relative to visit volume, there were no statistically sig-
nificant differences in the numbers of DDI pairs/between
the NMHCs and FQHCs (p = .74).
Among the 130 “definitely” and “likely” DDI pairs, we
found the largest categories of DDI pairs were related to
antihypertensive medications (n = 72, 55.4%) and war-
farin (n = 37, 28.4%) (Table 3). Although there may be
potential interacting effects, beta blockers are often pre-
scribed together with calcium channel blockers and alpha
agonists with careful monitoring. Warfarin prescribed
with antibiotics, synthroid and antiarrythmics may be a
clinical necessity requiring close monitoring. However,
warfarin prescribed with nonsteroidal anti-inflammatory
drugs (NSAIDs) has a higher level of potential interac-
tion. In an additional review with an expert pharmacist,
we found that most of the DDI pairs were drugs that
could be prescribed together—and in fact are often pre-
scribed together because both may be either needed clin-
ically for a short period of time (e.g., warfarin and certain
antibiotics) or their interacting effects can be managed
with close and appropriate monitoring (e.g., beta block-
ers and calcium channel blockers, warfarin and thyroid
hormone). All interactions except those for warfarin and
NSAIDs and ace inhibitors and potassium sparing diuret-
ics were identified as often or frequently prescribed to-
gether with close monitoring, or clinically necessary for
short periods of time.
Qualitative analysis results
Four main themes relevant to computer-generated DDI
alerts were identified in interviews. These themes are (a)
high sensitivity setting, (b) incomplete medication list or
expired drugs not being removed from the list, (c) alert
overriding and tolerance of interacting effects, and (d)
general appreciation of the value of computerized DDI
alerts.
High sensitivity setting. A majority of the end
users we interviewed deemed the sensitivity of the EHR’s
DDI alerting function was set too high. As one respondent
put it, “sometimes it overkills.” Users further commented
that it is very difficult to avoid interactions for mental
health patients who are on psychiatric drugs, and that it
is of little value for the system to alert on antibiotics and
birth control pills and food and alcohol.
Incomplete medication list or expired drugs
not being removed from the list. End users ac-
knowledged that the value of the system’s DDI alerting
function is largely undermined because many patients
do not have a complete medication list in the system:
“we tend sometimes not to update it as efficiently as we
should.” In addition, inactive drugs are not routinely re-
moved from the list, or are sometimes kept on the list
purposefully to provide a speedy view of the patient’s
entire medication history. Many interviewees also com-
mented that in ambulatory care settings it is practically
difficult to maintain a complete and accurate medication
list of patients. At one study site that services many “drop-
in” visits, for example, providers do not perceive main-
taining the mediation list for those patients who have a
very low likelihood of returning to the clinic the best use
of their clinical time.
Alert overriding and tolerance of interacting
effects. End users acknowledged that they commonly
overrode DDI alerts generated by the system because cer-
tain DDIs are oftentimes unavoidable: “we tell patients
there are interactions of this and this, but we have to
weigh the consequences . . . [we] do have a large number
of patients with psychiatric medications and they do in-
teract with a lot of other drugs.” They further commented
that they are consciously aware of the interacting effects
of certain pairs of drugs but they believe the effects can be
tolerated by the patient or can be alternatively managed:
“I have a lot of patients on purposeful interactions, a lot
. . . you know if you’re putting somebody on for a short
period of time, you take that risk.”
Appreciation of the value of computerized
DDI alerts. Despite concerns, the interviewees gener-
ally agreed that computerized DDI alerts could be useful.
This is especially among those providers who had prior
experiences witnessing severe consequences because of
DDI: “one time I felt very grateful that it, you know, saved
me.”
Discussion
Enhanced medication safety is a much anticipated ben-
efit of widespread adoption of EHRs and e-prescribing
capabilities. Our findings, based on five safety-net prac-
tices using the same EHR system, suggest that there were
indeed very few DDI pairs (0.01%) when accurate true
time overlaps were queried. The DDI pairs themselves
were also consistent with those reported in the previ-
ous literature from primary care in that they were re-
lated to cardiovascular medications and warfarin predom-
inantly (Wessel et al., 2010). Moreover, we found that
most of the DDI pairs identified were drugs that could be
prescribed together—and in fact are often prescribed to-
gether. These drugs do present potential DDIs; however,
they may be needed clinically for a short period of time,
or can be used together with close and appropriate moni-
toring and patient education if longer term use is needed.
Our qualitative data did confirm the presence of the
well-known phenomenon of alert fatigue (e.g., Isaac
et al., 2009). Although our rate of DDI pairs was ex-
traordinarily low, some clinicians in our study reported
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overriding the alerts and thought they were just too sen-
sitive. At the time of this study, the alert system in the
EHR did not require documentation as to why an alert
might be ignored or overridden. The upgraded version
of the EHR now includes that “forcing function” (Nanji
et al., 2011) in which a provider must enter a response as
to why an override has been selected.
In addition, the initial DDI alert system of the EHR used
in this study—not unlike other commercial products—
simply presented the severity and certainty of the DDI.
However, to obtain the necessary clinical details about the
specific DDI, the provider had to drill down into the alert
screen to obtain the particulars and recommended action.
A busy provider may not take the time to go further af-
ter an initial alert. The authors questioned whether the
initial alert message provided sufficient information to be
fully helpful to a busy clinician. As Nanji et al. (2011) sug-
gested, “specific drug decision support” would be help-
ful, and we are suggesting that this occur earlier in the
alert process. For example, if a provider prescribed war-
farin and an antibiotic and received an alert of “proba-
ble/major” yet found prescribing a clinical necessity, an
added specific detailed alert would be more useful and
helpful. A message such as “if prescription necessary for
short term, close monitoring of INR is essential” or “con-
sider prescribing an alternative antibiotic” or “additional
patient teaching may be needed.” A provider should not
have to go into several layers of information to receive
a fairly simple alert message that will either increase the
possibility of prescribing something else, or monitoring
appropriately if it is decided to be clinically necessary.
The current study highlights an additional concern of
the inaccuracy of alerts caused by missing end dates. The
significant lack of missing end dates may not only overes-
timate the number of actual DDIs, it may also lead to alert
fatigue and discounting alerts because some have irrele-
vant information. Orrico (2008) found that missing end
dates accounted for almost half of medication discrepan-
cies in a study that examined medication list reconcilia-
tion in an outpatient setting. In that study anti-infectives
and anti-inflammatory agents were found to be the most
common discrepancy offenders. In our data, missing end
dates involved more chronic disease and cardiac agents as
well as anti-infectives and anti-inflammatory agents.
With the growth of e-prescribing and medication rec-
onciliation during care transitions, having accurate medi-
cation lists—including end-date entry—is even more crit-
ical. By not having accurate end-date information, there
may be more unnecessary alerts with confusing and in-
correct information resulting in needless phone calls, in-
creased time and cost as well as choosing medications that
may not be the drug of choice in a particular situation
because of an avoidable DDI alert. Providers may not be
aware of the significance of entering end dates, as it is one
more step in the data entry process. Much more empha-
sis during implementation and training in this area may
be needed and/or evaluation of the prescribing functions
within the EHR from a usability perspective. It may also
be important to add a “forced function” as described by
Nanji et al. (2011) that requires the provider to enter an
end date.
Within the EHR itself it was not possible to track the ex-
tent to which providers responded to DDI alerts and chose
an alternative prescription, although with the very low
rate of DDIs by date overlap, we suspect providers did pay
attention to the alerts. While the system does not track
the effect of alerts on provider behavior, we know from
interviews that they do have some effect—despite the ex-
istence of reported alert fatigue. Given the extremely low
DDI pairs in this study, we believe the alerts avoided pre-
scriptions that would have created a potential or real DDI.
Interestingly in the qualitative interviews, the frequency
of psychiatric medication alerts frustrated providers in
one setting, yet when reviewing DDI pairs, there were no
such interactions among the pairs (and those pairs were
in the CMS 26 DDI pairs) indicating that the alerts may
have impacted prescribing choices. Having said that, the
sensitivity of the alert can be adjusted at both the practice
level and the user level. We do think giving individual
providers the ability to adjust the sensitivity may enhance
use acceptance. We suggest further research to examine
the potential unintended consequences from a safety per-
spective of giving providers individual control.
Because of the varied times of going live with the EHRs,
we were not able to analyze pre- and postimplementation
DDI pairs making it difficult to say that our low rate of
DDI pairs is fully related to the EHR. Yet, with such a low
rate of DDI pairs in this sample, and qualitative findings,
we believe the EHR played a very important role in this
low rate. We also did not verify records for documenta-
tion of rationale why a DDI alert might have been over-
ridden. Dosing and drug to disease interaction or moni-
toring of potential adverse events were also not addressed
in this analysis. We cannot say there was sound clinical
reasoning for the decisions made with the DDI pairs that
did occur, nor can we say the alert was ignored. It would
take a study that includes assessing the provider notes,
observing providers at the point of care and/or improved
EHR decision support recording to get to this level of
data. While Stage 1 of Meaningful Use only required that
drug–drug checking functionality be turned “on,” more
current and future stages of Meaningful Use will lead to
changes that improve both the software functionality re-
lated to DDI checking as well as encourage clinician adop-
tion related to the use of this new functionality. It is likely
that these advances in functionality will allow a deeper
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understanding of the effect of decision support on
provider behavior, patient outcomes, health information
exchange, and care coordination. New studies now need
to address these issues knowing that the upgraded EHR
will allow for this analysis.
Conclusion
Overall, findings from this study indicate an excep-
tionally low rate of DDI pairs among NP and physician
providers in these five safety-net practices after the imple-
mentation of the same EHR. We have added to the liter-
ature on prescribing and medication safety and the use of
an EHR in safety-net settings such as NMHCs and FQHCs.
Suggestions for changes to the EHR itself have been rec-
ommended, and some of those recommendations have
already occurred such as required rationale for overrid-
ing a “probable” or “certain” alert.
The significant lack of consistently recorded start and
end dates poses a severe limitation on the drug interac-
tion safety functionality in the EHR. Better understanding
of factors related to the failure of clinicians to record this
information from a usability perspective will be critical to
achieving the expected benefits.
Prescribers in this study included physicians and NPs
and no differences were found between them or between
the FQHC and NMHC settings in the rate of DDI pairs.
Training efforts during implementation are often short
changed (Nanji et al., 2011), but in the long run these
efforts lead to better utilization of the electronic prod-
uct and may also impact patient safety. This particular
study included a strong emphasis on a partnership model
throughout implementation and ongoing support that
may have impacted the overall use of the EHR and low
rate of DDI pairs.
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